

MEDIA RELEASE



Proteomics International's technical expertise and accreditation drives market share growth in world bio-generic markets

July 29, 2013 Perth, Australia. **Proteomics International, a global contract research organisation and accredited proteomics laboratory, is experiencing strong growth in the biosimilars and biologics markets. Revenue related to biosimilars has doubled in the last 12 months and turnover across the company is up 87% during the same period.** According to the Global Biosimilars Market Report 2013, these markets were estimated to be \$2bn in 2012 with a robust prediction to \$19.4bn in 2018 based on many drugs that will come off patent.

The Company has successfully undertaken a diverse range of projects to help demonstrate biosimilarity through a comprehensive and functional characterization of the proposed and reference products. The projects range from growth hormones to antibody biologics, and data packages provided to clients have been used for regulatory submission in the USA, Europe, India and China.

In addition to the high level of technical expertise and the most advanced suite of scientific instrumentation available, the Company became the world's first facility to receive ISO 17025 certification for its proteomics services (2009). This level of accreditation ensures laboratories generate technically valid results and strengthens the company's position to deliver data that is of the highest scientific integrity.

Dr Richard Lipscombe, Managing Director of Proteomics International, commented, "We have been successfully servicing the world markets since 2001 and have developed strong brand loyalty that delivers repeat business with key companies operating in the bio-generic markets. To further support our clients, we are pleased to announce the appointment of Dr Roopwant Judge, a highly experienced protein chemist and project manager, in a business development role to meet the fast growing demand centered in the Asia/Pacific."

"The collaborate effort with Proteomics International has resulted in measurable, tangible benefits for our biologic drug development initiatives," said Dr John Kaundinya, Chief Operating Officer of BSV Biosciences, a global research and drug development company with bases in the USA, India and Germany.

About Proteomics International

Proteomics International is privately owned, founded in 2001 with a sustainable business model that operates in three synergistic business units: Diagnostics (biomarker discovery and commercialization), Therapeutics (drug discovery of peptide medicines) and Analytics (CRO). The Company has discovered a panel of biomarkers for diabetic kidney disease and has self funded \$5 million to develop a proven protein biomarker discovery platform that could be used for other diseases (humans, veterinary and agriculture). The kidney disease biomarkers are now being cross validated in a highly curated clinical study with immunoassays and mass spectrometry to develop a diagnostic kit for the RUO, IVD, POC and CDx markets. Both diagnostic and prognostic studies are under way. The Company has also developed a proprietary protein drug discovery platform that analyzed proteins from venom to identify several potential lead compounds (analgesics and antimicrobials). The success rates for this process are 100 times greater than the industry standard hit-rate for small molecule primary screens.

More information

Mr Barry Epstein
Vice President Marketing / Commercialization
T +61 8 9389 1992
E barry@proteomics.com.au
W www.proteomics.com.au